Collaborative Neuroscience Network

1. E.R. Squibb & Sons, L.L.C. $4,647,685 16 payments
2. AstraZeneca UK Limited $1,887,741 5 payments
3. Celgene Corporation $1,038,629 5 payments
4. GlaxoSmithKline, LLC. $451,881 6 payments
5. H. Lundbeck A S $210,154 8 payments
6. Merck Sharp & Dohme Corporation $184,913 9 payments
7. AstraZeneca Pharmaceuticals LP $132,456 2 payments
8. Tolmar, Inc. $94,197 5 payments
9. Takeda Pharmaceuticals U.S.A., Inc. $87,031 9 payments
10. ACADIA Pharmaceuticals Inc $34,697 18 payments

1. A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants $3,235,161 1 payment
2. A Phase 1, Multi-center, Open-label, 3-arm, Fixed Sequence Study to Assess the Effect of Co-administration of AZD9833 on the Pharmacokinetics of Midazolam (CYP3A4/5 Substrate), of Omeprazole (CYP2C19 Substrate), of Celecoxib (CYP2C9 Substrate) and of Dabigatran etexilate (P-gp Transporter Substrate) in Healthy Postmenopausal Female Volunteers $1,844,549 2 payments
3. A Phase 1 Evaluation of the Safety, Tolerability, $1,020,772 1 payment
4. A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) $667,506 2 payments
5. A Phase 1, Open-Label, Randomized, Parallel Group, Single-Dose Clinica $451,881 6 payments
6. An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia $371,113 5 payments
7. An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia $215,319 3 payments
8. Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD) $210,154 8 payments
9. A Clinical Study to Evaluate a Cognitive Platform to Support Development of Symptomatic Therapies in Participants at Risk for Alzheimer s Disease $181,850 6 payments
10. Phase 1, Randomized, Open label, Three-arm, Single Dose, Parallel Group Study to Compare AZD7442 (AZD8895 and AZD1061) Pharmacokinetic Exposure Following Intramuscular Administration as a Co-formulation versus Administration from Two Separate Vials of the Individual Monoclonal Antibodies in Adult Healthy Participants $132,456 2 payments

1. Other $87,031 9 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.